Sign in
WithdrawnNo phase

Antiretroviral Therapy for Acute HIV Infection

Key facts

Who runs it
Henry M. Jackson Foundation for the Advancement of Military Medicine
Where
Uganda1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
17 Mar 2019
Ended
14 Sept 2025
Type of study
Interventional
Treatments tested
  • Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Record updated
26 April 2019
Why it stopped
Feeder cohort study closed.

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • First identified as an incident HIV infection within one year of estimated time of infection in RV 217
  • Willing to begin Genvoya® as soon as entering this study but not later than 7 days from study enrollment
  • Successfully passed Test of Understanding (TOU) with a score of 80% or more on ten questions after three attempts
  • Adult from 18 to 50 years of age
  • Able to participate for 96 weeks of study visits
  • In general good health as determined by the PI or his/her designee
  • Willing to have photo or fingerprint taken for identification purposes
  • No history of ART for any reason, i.e., treatment naïve and no HIV-post-exposure prophylaxis (PEP) or HIV-pre-exposure prophylaxis (PrEP)) within 90 days prior to enrollment
  • Willing to have blood samples collected and stored
  • Adequate renal function: estimated creatine clearance of >50 mL/min according to the Cockroft Gault formula 2 weeks prior to enrollment
  • Urine clean catch: glucose < trace and protein <1+ or as per site-specification 2 weeks prior to enrollment
  • Weight is > 35 kg
  • Female (only women of childbearing potential) Specific Criteria:; Negative pregnancy test 48 hours prior to enrollment:; Commits to continued use of adequate birth control method for 96 weeks of the study and prior to receiving study ART. Adequate birth control is defined as follows: Contraceptive medications delivered orally, intramuscularly, vaginally, or implanted, underneath the skin, surgical methods (hysterectomy or bilateral tubal ligation), condoms, diaphragms, intrauterine device (IUD), or abstinence. If depending on hormonal contraception, check package insert for drug interactions and/or consider adding a second barrier method

Who cannot take part

  • Requiring use of any medication that is contraindicated with Genvoya®. See Appendix I and the package insert
  • Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer, including but not limited to chronic hepatitis, renal insufficiency or failure; clinically significant forms of drug or alcohol abuse, mental illness, severe asthma, psychiatric disorders, heart disease, or cancer; or a physical finding on examination considered indicative of significant disease such as murmur (other than functional), hepatosplenomegaly, focal neurological deficit, etc
  • Untreated AIDS-related opportunistic infection
  • An AIDS defining condition diagnosed within 30 days
  • Positive Hepatitis B surface antigen at any time in the past
  • Women who are breast-feeding; There are no inclusion/exclusion criteria based on CD4 count because CD4 count can be transiently diminished during acute HIV infection and ART initiation during early or acute HIV infection offers the potential benefit of limiting reservoir seeding and preventing immune destruction regardless of peripheral CD4 count at the time of treatment initiation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will evaluate the virologic effect, safety and tolerability of Genvoya® in adults during early acute HIV infection.

The group in the trial

  • Genvoya 150Mg-150Mg-200Mg-10Mg TabletTreatment being tested

    Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 April 2019